2-(4-chloro-1,1-dioxo-2-phenyl-2,3-dihydro-1H-benzo[d]isothiazol-3-yl)acetic acid | 1087013-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-chloro-1,1-dioxo-2-phenyl-2,3-dihydro-1H-benzo[d]isothiazol-3-yl)acetic acid
• 英文别名: 2-(4-chloro-1,1-dioxo-2-phenyl-3H-1,2-benzothiazol-3-yl)acetic acid
• CAS: 1087013-06-6
• 化学式: C₁₅H₁₂ClNO₄S
• 分子量: 337.784
• InChiKey: VUUILBGEPVRVIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• AFFINITY ILLUDOFULVENE CONJUGATES
  申请人：AF Chemicals, LLC,

  公开号：US20210155583A1

  公开（公告）日：2021-05-27

  In an embodiment of the invention, a composition for treating a cell population comprises a medicant. The medicant moiety can be an illudofulvene analog. In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The affinity moiety can be an antibody, an antibody fragment, a receptor protein, a peptidic growth factor, an anti-angiogenic protein, a specific binding peptide, protease cleavable peptide, a glycopeptide, a peptide, a peptidic toxin, a protein toxin and an oligonucleotide. The affinity moiety can be covalently bound to the medicant via a linker.

  在该发明实施例中，用于治疗细胞群的组合物包括一种药物。该药物部分可以是伊卢多富烯类似物。在该发明实施例中，用于治疗细胞群的组合物包括亲和药物结合物（AMC）。亲和部分可以是抗体、抗体片段、受体蛋白、肽生长因子、抗血管生成蛋白、特异结合肽、蛋白酶可切割肽、糖肽、肽、肽毒素、蛋白毒素和寡核苷酸。亲和部分可以通过连接剂与药物共价结合。
• Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents
  申请人：Jirgensons Aigars

  公开号：US20100311741A1

  公开（公告）日：2010-12-09

  This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-α, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in the inhibition of TACE, and in the treatment of conditions that are ameliorated by the inhibition of TACE.

  本发明涉及治疗化合物领域，更具体地涉及某些双环磺酸（BCSA）化合物，其作为肿瘤坏死因子-α转化酶（TACE）的抑制剂。这些化合物对于治疗由TNF-α介导的疾病非常有用，例如类风湿性关节炎；炎症；银屑病；脓毒症休克；移植排斥；消瘦症；厌食症；充血性心力衰竭；缺血再灌注损伤后；中枢神经系统炎症性疾病；炎症性肠病；胰岛素抵抗；HIV感染；癌症；慢性阻塞性肺疾病（COPD）和哮喘。本发明还涉及包括这些化合物的制药组合物，以及这些化合物和组合物的使用，无论是体外还是体内，用于抑制TACE并治疗通过抑制TACE得到改善的疾病。
• PROCESS FOR PREPARING TETRAHYDROQUINOLINE DERIVATIVES
  申请人：Emde Ulrich

  公开号：US20100311976A1

  公开（公告）日：2010-12-09

  The invention relates to a novel process for preparing enantiomerically enriched or pure tetrahydroquinoline derivatives by reacting a chiral dihydropyran-methylamine C with a aldehyde B and an aniline A in a multicomponent one pot synthesis in the presence of a protonic acid or Lewis acid with a suitable solvent. A, B, C have the meaning as described in the specification.

  本发明涉及一种新型的工艺，通过在质子酸或路易斯酸的适当溶剂存在下，将手性二氢吡喃-甲基胺C与醛B和苯胺A在多组分一锅法合成中反应，制备对映体富集或纯的四氢喹啉衍生物。其中，A、B、C的含义如规范中所述。
• Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
  申请人：PHARMAKEA, INC.

  公开号：US10774069B2

  公开（公告）日：2020-09-15

  Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了赖氨酰氧化酶样2（LOXL2）抑制剂（3-(4-(氨基甲基)-6-(三氟甲基)吡啶-2-基氧基)苯基)((3R,4R)-3-氟-4-羟基吡咯烷-1-基)甲酮的药学上可接受的盐的结晶形式。还描述了制造LOXL2抑制剂的方法，包含LOXL2抑制剂的药物组合物和药物，以及使用LOXL2抑制剂治疗与LOXL2活性相关的病症、疾病或紊乱的方法。
• Plant growth regulator compounds
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：US11136292B2

  公开（公告）日：2021-10-05

  The present invention relates to relates to novel strigolactone derivatives of formula (I), to processes for preparing these derivatives including intermediate compounds, to seeds comprising these derivatives, to plant growth regulator or seed germination promoting compositions comprising these derivatives and to methods of using these derivatives in controlling the growth of plants and/or promoting the germination of seeds.

  本发明涉及式（I）的新型绞股蓝内酯衍生物、制备这些衍生物（包括中间体化合物）的工艺、包含这些衍生物的种子、包含这些衍生物的植物生长调节剂或促进种子萌发的组合物，以及使用这些衍生物控制植物生长和/或促进种子萌发的方法。